, Department of pharmacy

, Montréal, QC, Canada 4. Division of Microbiology and Infectious Diseases

R. P. Perrillo, R. Gish, and Y. T. Falck-ytter, American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy, Gastroenterology, vol.148, issue.1, pp.221-244, 2015.

R. Loomba and T. J. Liang, Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions, Gastroenterology, vol.152, issue.6, pp.1297-309, 2017.

J. P. Hwang, M. R. Somerfield, A. De, D. R. Cryer, J. J. Feld et al.,

, Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update, J Clin Oncol, 2015.

C. Research, FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immunesuppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). FDA [Internet, 2019.

J. Lee, J. Y. Park, D. G. Kim, J. Y. Lee, B. S. Kim et al., Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation, Sci Rep, vol.8, issue.1, pp.1-8, 2018.

A. Visram, K. Chan, P. Mcgee, J. Boro, L. K. Hicks et al., Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening, PloS One, vol.10, issue.4, p.120749, 2015.

S. D. Ramsey, J. M. Unger, L. H. Baker, R. F. Little, R. Loomba et al., Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices, JAMA Oncol

, Apr, vol.1, issue.4, pp.497-505

J. P. Hwang, M. J. Fisch, H. Zhang, M. A. Kallen, M. J. Routbort et al., Low Rates of Hepatitis B Virus Screening at the Onset of Chemotherapy, J Oncol Pract, 2012.

J. P. Hwang, M. J. Fisch, A. Lok, H. Zhang, J. M. Vierling et al., Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center, BMC Cancer, vol.13, p.534, 2009.

C. S. Voican, O. Mir, P. Loulergue, M. Dhooge, C. Brezault et al., Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment, Ann Oncol Off J Eur Soc Med Oncol, vol.27, issue.12, pp.2172-84, 2016.

, S1 -Hepatitis B screening before treatment with rituximab

, Rossy Cancer Network, 2019.

K. R. Reddy, K. L. Beavers, S. P. Hammond, J. K. Lim, and Y. T. Falck-ytter, American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

, Gastroenterology, vol.148, issue.1, pp.215-224, 2015.

S. Paul, A. Saxena, N. Terrin, K. Viveiros, E. M. Balk et al., Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis, Ann Intern Med, vol.164, issue.1, pp.30-40, 2016.

G. Lau, H. Yiu, D. Fong, H. Cheng, W. Au et al., Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy, Gastroenterology, vol.125, issue.6, pp.1742-1751, 2003.

J. W. Jang, J. Y. Choi, S. H. Bae, S. K. Yoon, U. I. Chang et al., A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization

, Hepatology, vol.43, issue.2, pp.233-273, 2006.

C. Hsu, C. A. Hsiung, I. Su, W. Hwang, M. Wang et al., A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non

, Hodgkin's lymphoma: a randomized trial, Hepatol Baltim Md, vol.47, issue.3, pp.844-53, 2008.

Y. Huang, L. Hsiao, Y. Hong, T. Chiou, Y. Yu et al., Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B, J Clin Oncol Off J Am Soc Clin Oncol, vol.31, issue.22, pp.2765-72, 2013.

M. Zhang, G. Zhu, K. Shi, J. Zheng, Z. Cheng et al., Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation, Oncotarget

C. Yang, B. Qin, Z. Yuan, L. Chen, and H. Zhou, Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation, Ann Hepatol, vol.15, issue.4, pp.501-512, 2016.

S. Yu, H. Luo, M. Pan, A. P. Luis, Z. Xiong et al., Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis, Int J Clin Pharm, vol.38, issue.5, pp.1035-1078, 2016.

N. A. Terrault, A. Lok, B. J. Mcmahon, K. Chang, J. P. Hwang et al., Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance, Hepatol Baltim Md, vol.67, issue.4, pp.1560-99, 2018.

, European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection, J Hepatol, vol.57, issue.1, pp.167-85, 2012.

C. M. Weinbaum, I. Williams, E. E. Mast, S. A. Wang, L. Finelli et al., Recommendations for identification and public health management of persons with chronic hepatitis B virus infection, MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep, vol.57, issue.8, pp.1-20, 2008.

U. Zurawska, L. K. Hicks, G. Woo, C. M. Bell, M. Krahn et al., Hepatitis B Virus Screening Before Chemotherapy for Lymphoma: A Cost-Effectiveness Analysis, J Clin Oncol, vol.30, issue.26, pp.3167-73, 2012.

F. L. Day, J. Karnon, and D. Rischin, Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors, J Clin Oncol, vol.29, issue.24, pp.3270-3277, 2011.

K. Leber, J. Otten, A. Depla, D. Brandjes, and F. N. Lauw, Introduction of routine hepatitis B screening for all patients receiving cancer treatment, Neth J Med, 2019.

L. K. Hicks, P. Leung, and J. Cape, Screening for hepatitis B virus prior to chemotherapy: A quality improvement project, J Clin Oncol, vol.31, pp.158-158, 2013.

M. K. Sammons, D. Patel, K. Sepkowitz, E. J. Sherman, and R. B. ,

A. D. Mendelsohn, E. Zelenetz, and . Ludwig, Successful implementation of a universal screening program to prevent hepatitis B reactivation in a large cancer center

, Hepatology, vol.58, issue.S1, p.848, 2013.

, Hepatitis B -Chapter 4 -2020 Yellow Book | Travelers' Health | CDC, 2019.

A. Visram and J. J. Feld, Defining and grading HBV reactivation: Defining and Grading HBV Reactivation. Clin Liver Dis, vol.5, pp.35-43, 2015.

A. Sanagawa, J. Kuroda, A. Shiota, N. Kito, M. Takemoto et al., Outcomes of the implementation of the computer-assisted HBView system for the prevention of hepatitis B virus reactivation in chemotherapy patients: a retrospective analysis, J Pharm BIBLIOGRAPHIE

, World Health Organization, World Health Organization, Department of HIV/AIDS. Guidance on prevention of viral hepatitis B and C among people who inject drugs, 2012.

D. Sur,

F. Santé-publique, , 2019.

D. Sur,

D. Sur,

B. Hepatitis, 2020 Yellow Book | Travelers' Health | CDC, 2019.

D. Sur,

R. Salpini, A. Battisti, L. Colagrossi, D. Carlo, D. Fabeni et al., A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection, J Viral Hepat. juill, vol.26, issue.7, pp.846-55, 2019.

C. M. Weinbaum, I. Williams, E. E. Mast, S. A. Wang, L. Finelli et al., Recommendations for identification and public health management of persons with chronic hepatitis B virus infection, MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep. 19 sept, vol.57, issue.8, pp.1-20, 2008.

, European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection, J Hepatol. juill, vol.57, issue.1, pp.167-85, 2012.

J. Lupberger and E. Hildt, Hepatitis B virus-induced oncogenesis, World J Gastroenterol WJG. 7 janv, vol.13, issue.1, p.74, 2007.

P. A. Revill and S. A. Locarnini, New perspectives on the hepatitis B virus life cycle in the human liver, J Clin Invest, vol.126, issue.3, pp.833-839

J. E. Song and D. Y. Kim, Diagnosis of hepatitis B, Ann Transl Med, vol.4, issue.18, p.338, 2016.

P. Halfon, S. Pol, M. Bourlière, and P. Cacoub, Les génotypes du virus de l'hépatite B, Gastroenterol Clin Biol, vol.26, pp.1005-1012, 2002.

G. A. Poland, Clinical practice : prevention of Hepatitis B with the Hepatitis B Vaccine, N Engl J Med, vol.351, issue.27, pp.2832-2840, 2004.

H. Momméja-marin, H. Zylberberg, and S. Pol, Vaccination prophylactique contre l'hépatite B : actualité et avenir, Gastroenterol Clin Biol, vol.23, issue.4, p.453, 1999.

A. Nationale-de-sécurité-du and M. , Résumé des Caractéristiques du Produit : Engerix B [en ligne, 2016.

, European Comission. Résumé des Caractéristiques du Produit : HBVAXPRO

C. Gouvernement-du, Vaccin contre l'hépatite B : Guide canadien d'immunisation [en ligne, 2007.

S. Ministère-des, L. De, and . Santé, Calendrier des vaccinations et recommandations vaccinales, 2019.

. Santé-publique-france and . Hépatites, , 2019.

F. J. Mahoney, Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection, Clin Microbiol Rev. avr, vol.12, issue.2, pp.351-66, 1999.

W. E. Abara, A. Qaseem, S. Schillie, B. J. Mcmahon, and A. M. Harris, for the High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention. Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention, Ann Intern Med. 5 déc, vol.167, issue.11, p.794, 2017.

N. A. Terrault, A. Lok, B. J. Mcmahon, K. Chang, J. P. Hwang et al., Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance, Hepatol Baltim Md, vol.67, issue.4, pp.1560-99, 2018.

, Hepatitis B (Chronic): Diagnosis and Management of Chronic Hepatitis B in Children, Young People and Adults

. London, National Institute for Health and Care Excellence (UK), 2013.

D. Sur,

A. Lok and B. J. Mcmahon, Chronic hepatitis B: update 2009, Hepatol Baltim Md. sept, vol.50, issue.3, pp.661-663, 2009.

A. S. Ray, M. W. Fordyce, and M. Hitchcock, Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus, Antiviral Res. 1 janv, vol.125, pp.63-70, 2016.

A. Visram and J. J. Feld, Defining and grading HBV reactivation: Defining and Grading HBV Reactivation, Clin Liver Dis. févr, vol.5, issue.2, pp.35-43, 2015.

A. S. Lok, R. H. Liang, E. K. Chiu, K. L. Wong, T. K. Chan et al., Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy

, Gastroenterology. janv, vol.100, issue.1, pp.182-190, 1991.

D. Bisceglie, A. M. Lok, A. S. Martin, P. Terrault, N. Perrillo et al., Recent US Food and Drug Administration warnings on hepatitis B reactivation with immunesuppressing and anticancer drugs: just the tip of the iceberg?, Hepatol Baltim Md. févr, vol.61, issue.2, pp.703-714, 2015.

R. Loomba, A. Rowley, R. Wesley, T. J. Liang, J. H. Hoofnagle et al., Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy, Ann Intern Med. 1 avr, vol.148, issue.7, pp.519-547, 2008.

R. Loomba and T. J. Liang, Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions, Gastroenterology. mai, vol.152, issue.6, pp.1297-309, 2017.

J. P. Hwang, M. R. Somerfield, A. De, D. R. Cryer, J. J. Feld et al.,

, Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update, J Clin Oncol. juill, vol.33, pp.2212-2232, 2015.

D. Food and . Administration, FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immunesuppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab)

D. Sur,

J. Lee, J. Y. Park, D. G. Kim, J. Y. Lee, B. S. Kim et al., Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation. Sci Rep, vol.8, pp.1-8, 2018.

J. P. Hwang, M. J. Fisch, A. Lok, H. Zhang, J. M. Vierling et al., Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center, BMC Cancer, vol.13, p.534, 2013.

W. Yeo, P. Chan, P. Hui, W. M. Ho, K. C. Lam et al., Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study, J Med Virol. 1 août, vol.70, issue.4, pp.553-61, 2003.

S. Barclay, S. Pol, D. Mutimer, Y. Benhamou, P. R. Mills et al., The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting, J Clin Virol. 1 avr, vol.41, issue.4, pp.243-54, 2008.

M. Ya?c?, Z. N. Özkurt, Z. A. Ye?in, Z. Ak?, G. T. Sucak et al., Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies, Hematology. 1 août, vol.15, issue.4, pp.240-244, 2010.

Y. M. Kim, S. Jeong, J. Kim, S. H. Lee, J. H. Hwang et al., Chronic hepatitis B, non-Hodgkin's lymphoma, and effect of prophylactic antiviral therapy, J Clin Virol. 1 août, vol.51, issue.4, pp.241-246, 2011.

D. Mya, S. T. Han, Y. C. Linn, W. Hwang, Y. T. Goh et al., Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection, Ann Oncol. 1 févr, vol.23, issue.2, pp.421-427, 2012.

A. D. Zelenetz, W. G. Wierda, J. S. Abramson, R. H. Advani, C. B. Andreadis et al., Non-Hodgkin's Lymphomas

, JNCCN J Natl Compr Cancer Netw. 1 déc, vol.10, issue.12, pp.1487-98, 2012.

R. Idilman and M. Arat, Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation, Expert Rev Anti Infect Ther. 1 août, vol.9, issue.8, pp.641-52, 2011.

W. Yeo, T. C. Chan, N. Leung, W. Y. Lam, F. Mo et al., Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab, J Clin Oncol. 15 déc, vol.27, issue.4, pp.605-616, 2008.

Y. Tsutsumi, Hepatitis B virus reactivation with a rituximab-containing regimen, World J Hepatol, vol.7, issue.21, p.2344, 2015.

J. Méndez-navarro, K. E. Corey, H. Zheng, L. L. Barlow, J. Y. Jang et al., Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy

, Liver Int, vol.31, issue.3, pp.330-339, 2011.

A. M. Evens, B. D. Jovanovic, Y. Su, D. W. Raisch, D. Ganger et al.,

, Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports, Ann Oncol. 1 mai, vol.22, issue.5, pp.1170-80, 2011.

C. Leung, E. Tsoi, G. Burns, and W. Sievert, An Argument for the Universal Prophylaxis of Hepatitis B Infection in Patients Receiving Rituximab: A 7-Year Institutional Experience of Hepatitis Screening, The oncologist. 1 avr, vol.16, pp.579-84, 2011.

A. Cheng, C. A. Hsiung, I. Su, P. Chen, M. Chang et al., Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma, Hepatology, vol.37, issue.6, pp.1320-1328, 2003.

R. Tur-kaspa, R. D. Burk, Y. Shaul, and D. A. Shafritz, Hepatitis B virus DNA contains a glucocorticoid-responsive element, Proc Natl Acad Sci, vol.83, issue.6, p.1627, 1986.

E. Iannitto, V. Minardi, G. Calvaruso, A. Mulè, E. Ammatuna et al., Hepatitis B virus reactivation and alemtuzumab therapy, Eur J Haematol, vol.74, issue.3, pp.254-262, 2005.

T. Aomatsu, H. Komatsu, A. Yoden, A. Hosomi, H. Miyazaki et al., Fulminant hepatitis B and acute hepatitis B due to intrafamilial transmission of HBV after chemotherapy for non-Hodgkin's lymphoma in an HBV carrier, Eur J Pediatr. 24 mai, vol.169, issue.2, p.167, 2009.

A. Rago, L. Ridola, and M. Lichtner, Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine, J Antimicrob Chemother, vol.67, issue.2, pp.510-511, 2012.

U. Tapan, S. K. May, J. Fiore, and O. Kozyreva, Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma, Leuk Lymphoma. 1 mai, vol.52, issue.5, pp.916-924, 2011.

K. Ikeda, Y. Shiga, A. Takahashi, T. Kai, H. Kimura et al., Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment, Leuk Lymphoma. 1 janv, vol.47, issue.1, pp.155-162, 2006.

C. Hsu, H. Hsu, H. Chen, M. Gao, P. Yeh et al., Doxorubicin Activates Hepatitis B Virus (HBV) Replication in HBV-harboring Hepatoblastoma Cells. A Possible Novel Mechanism of HBV Reactivation in HBV Carriers Receiving Systemic Chemotherapy, ANTICANCER Res, vol.6, 2004.

C. Hui, A. Lie, W. Au, Y. Leung, S. Ma et al., A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation, Blood. 15 juill, vol.106, issue.2, pp.464-473, 2005.

S. P. Hammond, A. M. Borchelt, C. Ukomadu, V. T. Ho, L. R. Baden et al., Hepatitis B Virus Reactivation following Allogeneic Hematopoietic Stem Cell Transplantation, Biol Blood Marrow Transplant. 1 sept, vol.15, issue.9, pp.1049-59, 2009.

J. Yun, K. H. Kim, E. S. Kang, G. Gwak, M. S. Choi et al., Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy, Br J Cancer. févr, vol.104, issue.4, pp.559-63, 2011.

S. Zhong, W. Yeo, C. Schroder, P. Chan, W. Wong et al., High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy, J Viral Hepat, vol.11, issue.1, pp.55-64, 2004.

G. Lau, Hepatitis B reactivation after chemotherapy: two decades of clinical research

, Hepatol Int. juin, vol.2, issue.2, pp.152-62, 2008.

P. Borentain, P. Colson, D. Coso, E. Bories, A. Charbonnier et al., Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer, J Viral Hepat, vol.17, issue.11, pp.807-822, 2010.

K. R. Reddy, K. L. Beavers, S. P. Hammond, J. K. Lim, and Y. T. Falck-ytter, American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

, Gastroenterology. janv, vol.148, issue.1, pp.215-224, 2015.

A. S. Artz, M. R. Somerfield, J. J. Feld, A. F. Giusti, B. S. Kramer et al., American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases, J Clin Oncol Off J Am Soc Clin Oncol. 1 juill, vol.28, pp.3199-202, 2010.

W. Yeo, B. Zee, and S. Zhong, Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy, Br J Cancer, vol.90, issue.7, pp.1306-1311, 2004.

G. Lau, Y. Leung, D. Fong, W. Au, Y. Kwong et al., High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation, Blood. 1 avr, vol.99, issue.7, pp.2324-2354, 2002.

C. Hsu, C. A. Hsiung, I. Su, W. Hwang, M. Wang et al., A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial, Hepatol Baltim Md. mars, vol.47, issue.3, pp.844-53, 2008.

G. Lau, H. Yiu, D. Fong, H. Cheng, W. Au et al., Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy, Gastroenterology. déc, vol.125, issue.6, pp.1742-1751, 2003.

P. D. Ziakas, P. Karsaliakos, and E. Mylonakis, Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance, Haematologica. juill, vol.94, issue.7, pp.998-1005, 2009.

S. Saab, M. H. Dong, T. A. Joseph, and M. J. Tong, Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: A decision analysis model, Hepatology, vol.46, issue.4, pp.1049-56, 2007.

H. Hann, V. Gregory, J. Dixon, and K. Barker, A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B : Lamivudine resistance

, Hepatol Int. 1 janv, vol.2, pp.440-56, 2009.

R. G. Gish, A. S. Lok, T. Chang, R. A. Man, . De et al., Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B

, Gastroenterology, vol.133, issue.5, pp.1437-1481, 2007.

C. Lai, D. Shouval, A. S. Lok, T. Chang, H. Cheinquer et al., Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B, N Engl J Med. 9 mars, vol.354, issue.10, pp.1011-1031, 2006.

H. Li, J. Huang, H. Guo, X. Zhang, Y. Xie et al., Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy, J Viral Hepat. déc, vol.18, issue.12, pp.877-83, 2011.

H. Kojima, H. Tsujimura, T. Sugawara, N. Mimura, M. Ise et al., Prospective study of hepatitis b virus reactivation in hbsag-negative patients after chemotherapy with rituximab: hbv-dna monitoring and entecavir prophylaxis, J Hepatol. 1 avr, vol.56, p.206, 2012.

S. Yu, H. Luo, M. Pan, A. P. Luis, Z. Xiong et al., Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis, Int J Clin Pharm, vol.38, issue.5, pp.1035-1078, 2016.

F. W. Chen, L. Coyle, B. E. Jones, and V. Pattullo, Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease, Liver Int Off J Int Assoc Study Liver. sept, vol.33, issue.8, pp.1203-1213, 2013.

H. Huang, X. Li, J. Zhu, S. Ye, H. Zhang et al., Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial, JAMA. 17 déc, vol.312, issue.23, pp.2521-2551, 2014.

Y. Huang, L. Hsiao, Y. Hong, T. Chiou, Y. Yu et al., Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B, J Clin Oncol Off J Am Soc Clin Oncol. 1 août, vol.31, issue.22, pp.2765-72, 2013.

J. P. Hwang, J. M. Vierling, A. D. Zelenetz, S. C. Lackey, and R. Loomba, Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.20, pp.2999-3008, 2012.

L. R. Baden, S. Swaminathan, M. Angarone, G. Blouin, B. C. Camins et al., Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Cancer Netw JNCCN, vol.14, issue.7, pp.882-913, 2016.

, Institute of Medicine (US) Committee on the Prevention and Control of Viral Hepatitis Infection. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C

H. M. Colvin and A. E. Mitchell,

U. Zurawska, L. K. Hicks, G. Woo, C. M. Bell, M. Krahn et al., Hepatitis B Virus Screening Before Chemotherapy for Lymphoma: A Cost-Effectiveness Analysis, J Clin Oncol, vol.30, issue.26, pp.3167-73, 2012.

J. P. Hwang, D. Huang, and J. M. Vierling, Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy, JCO Clin Cancer Inform, vol.3, pp.1-12, 2019.

F. L. Day, J. Karnon, and D. Rischin, Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors, J Clin Oncol. 25 juill, vol.29, issue.24, pp.3270-3277, 2011.

T. T. Tran, M. O. Rakoski, P. Martin, and F. Poordad, Screening for hepatitis B in chemotherapy patients: survey of current oncology practices, Aliment Pharmacol Ther. 15 janv, vol.31, issue.2, pp.240-246, 2010.

J. P. Hwang, M. J. Fisch, H. Zhang, M. A. Kallen, M. J. Routbort et al., Low Rates of Hepatitis B Virus Screening at the Onset of Chemotherapy, J Oncol Pract. juill, vol.8, issue.4, pp.32-41, 2012.

S. D. Ramsey, J. M. Unger, L. H. Baker, R. F. Little, R. Loomba et al., Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices, JAMA Oncol. 1 avr, vol.5, issue.4, pp.497-505, 2019.

C. S. Voican, O. Mir, P. Loulergue, M. Dhooge, C. Brezault et al., Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment, Ann Oncol Off J Eur Soc Med Oncol, vol.27, issue.12, pp.2172-84, 2016.

N. Rossy-cancer, S1-Hepatitis B screening before treatment with rituximab, 2018.

S. Y. Lin, E. T. Chang, and S. K. So, Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatol Baltim Md, vol.46, pp.1034-1074, 2007.

J. P. Hwang, M. Mohseni, B. J. Gor, S. Wen, H. Guerrero et al., Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening, Am J Public Health. 1 avr, vol.100, issue.1, pp.118-124, 2010.

K. Leber, J. Otten, A. Depla, D. Brandjes, and F. N. Lauw, Introduction of routine hepatitis B screening for all patients receiving cancer treatment, Neth J Med. janv, vol.77, issue.1, pp.19-24, 2019.

M. K. Sammons, D. Patel, K. Sepkowitz, E. J. Sherman, and R. B. ,

A. D. Mendelsohn, E. Zelenetz, and . Ludwig, Successful implementation of a universal screening program to prevent hepatitis B reactivation in a large cancer center

, Hepatology, vol.58, issue.S1, p.848, 2013.

A. Sanagawa, J. Kuroda, A. Shiota, N. Kito, M. Takemoto et al., Outcomes of the implementation of the computer-assisted HBView system for the prevention of hepatitis B virus reactivation in chemotherapy patients: a retrospective analysis, J Pharm Health Care Sci, vol.1, p.29, 2015.

L. K. Hicks, P. Leung, and J. Cape, Screening for hepatitis B virus prior to chemotherapy: A quality improvement project, J Clin Oncol, vol.31, pp.158-158, 2013.

R. Lee, K. Vu, C. M. Bell, and L. K. Hicks, Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement, Curr Oncol, vol.17, issue.6, pp.32-40, 2010.

A. S. Köksal, B. Toka, A. T. Eminler, I. Hac?bekiro?lu, C. Sunu et al., The efficacy of a computer alert programme for increasing HBV screening rates before starting immunosuppressive therapy, Acta Gastro-Enterol Belg. juin, vol.82, issue.2, pp.279-84, 2019.

H. Tilly, M. Gomes-da-silva, U. Vitolo, A. Jack, M. Meignan et al., Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Algorithme décisionnel du CHUM sur le dépistage, vol.26, pp.116-141, 2015.